EP4456901A4 - Composition pharmaceutique d'empagliflozine et de linagliptine traitée par extrusion à chaud - Google Patents

Composition pharmaceutique d'empagliflozine et de linagliptine traitée par extrusion à chaud

Info

Publication number
EP4456901A4
EP4456901A4 EP22917050.1A EP22917050A EP4456901A4 EP 4456901 A4 EP4456901 A4 EP 4456901A4 EP 22917050 A EP22917050 A EP 22917050A EP 4456901 A4 EP4456901 A4 EP 4456901A4
Authority
EP
European Patent Office
Prior art keywords
empagliflozin
linagliptin
processed
pharmaceutical composition
melt extrusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22917050.1A
Other languages
German (de)
English (en)
Other versions
EP4456901A1 (fr
Inventor
Burcin Yanc
Bozyel Muge Ulusoy
Fatih Sunel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Priority claimed from PCT/TR2022/051598 external-priority patent/WO2023129050A1/fr
Publication of EP4456901A1 publication Critical patent/EP4456901A1/fr
Publication of EP4456901A4 publication Critical patent/EP4456901A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP22917050.1A 2021-12-28 2022-12-26 Composition pharmaceutique d'empagliflozine et de linagliptine traitée par extrusion à chaud Pending EP4456901A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR202121295 2021-12-28
PCT/TR2022/051598 WO2023129050A1 (fr) 2021-12-28 2022-12-26 Composition pharmaceutique d'empagliflozine et de linagliptine traitée par extrusion à chaud

Publications (2)

Publication Number Publication Date
EP4456901A1 EP4456901A1 (fr) 2024-11-06
EP4456901A4 true EP4456901A4 (fr) 2025-12-10

Family

ID=93014666

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22917050.1A Pending EP4456901A4 (fr) 2021-12-28 2022-12-26 Composition pharmaceutique d'empagliflozine et de linagliptine traitée par extrusion à chaud

Country Status (1)

Country Link
EP (1) EP4456901A4 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190290588A1 (en) * 2018-03-26 2019-09-26 Hetero Labs Limited Stable bilayer tablet compositions
WO2021123165A1 (fr) * 2019-12-19 2021-06-24 Krka, D.D., Novo Mesto Forme posologique comprenant une solution solide amorphe d'empagliflozine avec un polymère

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190290588A1 (en) * 2018-03-26 2019-09-26 Hetero Labs Limited Stable bilayer tablet compositions
WO2021123165A1 (fr) * 2019-12-19 2021-06-24 Krka, D.D., Novo Mesto Forme posologique comprenant une solution solide amorphe d'empagliflozine avec un polymère

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PARK JUN-BOM ET AL: "New investigation of distribution imaging and content uniformity of very low dose drugs using hot-melt extrusion method", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, AMSTERDAM, NL, vol. 458, no. 2, 21 October 2013 (2013-10-21), pages 245 - 253, XP028782913, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2013.10.027 *
See also references of WO2023129050A1 *

Also Published As

Publication number Publication date
EP4456901A1 (fr) 2024-11-06

Similar Documents

Publication Publication Date Title
EP3481831A4 (fr) Nouveaux dérivés de 4-aminopyrazolo [3,4-d]pyrimidinylazabicyclo et compositions pharmaceutiques les contenant
WO2015023675A3 (fr) Comprimé extrudé anti-abus à libération immédiate
EP3452026A4 (fr) Procédés de fabrication, compositions et applications médicales de produits pharmaceutiques à base de cannabis administrés par voie orale
EP4209513A4 (fr) Anticorps bispécifique anti-vegf-anti-pd-l1, composition pharmaceutique de celui-ci et utilisations associées
EP4389752A4 (fr) Dérivé de camptothécine, composition pharmaceutique et leur utilisation
WO2014170755A3 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
EP3786167C0 (fr) Composé macrocyclique diaryle, composition pharmaceutique et utilisation associée
EP3584245A4 (fr) Dérivé antibactérien de triazole, composition pharmaceutique et utilisation associées
EP4095158A4 (fr) Composition pharmaceutique contenant un anticorps anti-btla et son utilisation
EP4431513A4 (fr) Dérivé de carbamoylpyridone polycyclique, son procédé de préparation et composition pharmaceutique de celui-ci
EP4314033A4 (fr) Protéines de fusion, compositions pharmaceutiques et applications thérapeutiques
EP3453393A4 (fr) Nouveaux dérivés de quinazolinone inhibant la pi3k et composition pharmaceutique en contenant
EP3760191A4 (fr) Composition pharmaceutique, procédé de préparation et utilisation de cette dernière
EP4434981A4 (fr) Composé à cinq et six chaînons, son procédé de préparation et composition pharmaceutique et son utilisation
EP4385988A4 (fr) Dérivé de triazole substitué, son procédé de préparation, composition pharmaceutique de celui-ci et utilisation associée
EP3560921A4 (fr) Composé de quinazoline et procédé de préparation, utilisation et composition pharmaceutique correspondantes
WO2016040814A3 (fr) Polymères de bisulfure et procédés d'utilisation associés
EP4456901A4 (fr) Composition pharmaceutique d'empagliflozine et de linagliptine traitée par extrusion à chaud
EP4205745A4 (fr) Composition pharmaceutique de cariprazine, méthode de préparation et son application
EP4171611A4 (fr) Protéines de fusion de l'interleukine-22, leurs compositions pharmaceutiques et leurs applications thérapeutiques
EP3792253A4 (fr) Composé ayant une nouvelle structure, complexe le comprenant, composition pharmaceutique anticancéreuse et médicament anticancéreux
EP4342900C0 (fr) Dérivés de sesquiterpène et compositions pharmaceutiques de ceux-ci, leur procédé de préparation et leur utilisation
EP3821911A4 (fr) Nanoparticules d'acides nucléiques, composition pharmaceutique les comprenant , médicament comprenant de la doxorubicine, et procédé de préparation associé
EP3595714A4 (fr) Immunopotentialisateur, composition pharmaceutique immunothérapique et sa préparation et utilisation
EP3638209A4 (fr) Compositions de nanoparticules, leurs procédés de fabrication et utilisation pour l'administration de médicaments

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240610

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_62575/2024

Effective date: 20241125

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOVEL ILAC SANAYI VE TICARET A.S.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20251110

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7048 20060101AFI20251104BHEP

Ipc: A61K 31/522 20060101ALI20251104BHEP

Ipc: A61K 45/06 20060101ALI20251104BHEP

Ipc: A61K 9/20 20060101ALI20251104BHEP

Ipc: A61K 9/16 20060101ALI20251104BHEP